Ewha Med J.  1993 Dec;16(4):337-340. 10.12771/emj.1993.16.4.337.

Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer

• Lee SN

• KMID: 1965085
• DOI: http://doi.org/10.12771/emj.1993.16.4.337

Abstract

To evaluste the efficacy and toxicity of IEP chemotherapy in locally advanced and metastatic non-small cell lung cancer, nineteen previously untreated patients with non-small cell lung cancer were studied. Patients received ifosfamide 1000mg/m2 with mesna, 20% of ifosfamide dose at 0,4, 8 hours after ifosfamide, etoposide 100mg/m2, and cisplatin 20mg/m2 with full hydration and mannitol diuresis intravenously on days 1-3 every 4 weeks. Eighteen male and one female, two stage IIIA, 10 stage IIIB and 7 stage IV patients have been treated. The response rate of IEP was 26% with no complete remission, 53% of stable disease, and 23% of progressive diasease. The overall median survival was not reaced yet and 20 month survival rate was 51.4%, The duration of remission was at the range of 4+ to 40 weeks. The toxicities were alopecia(100%), nausea and vomiting(47%), leukopenia(14%), infection(6%), renal dysfunction(6%) and oral mucositis(5%). This phase II study of IEP in advanced non-small cell lung cancer is not superior to another combination regimens in terms of response but toxicity was tolerable. Other new chemotherapeutic drugs and newer trials should be developed further.

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin
Diuresis
Drug Therapy*
Etoposide*
Female
Humans
Ifosfamide*
Male
Mannitol
Mesna
Nausea
Survival Rate
Cisplatin
Etoposide
Ifosfamide
Mannitol
Mesna